Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724467 | 0.91 | LMNA (0.51) | LMNAPOLBSMN1; SMN2GAAGBA2 | |
| SCHEMBL9285131 | 0.91 | LMNA (0.51) | LMNAPOLBSMN1; SMN2GAAGBA2 | |
| SCHEMBL7448604 | 0.88 | LMNA (0.55) | LMNAPOLBSMN1; SMN2GAAGBA2 | |
| SCHEMBL16256877 | 0.87 | LMNA (0.58) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL11974037 | 0.87 | POLB (0.58) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL28787851 | 0.86 | POLB (0.54) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL7985579 | 0.86 | LMNA (0.56) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL3994255 | 0.86 | POLB (0.56) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL30510136 | 0.86 | SMN1; SMN2 (0.56) | LMNAPOLBSMN1; SMN2GAAATM | |
| SCHEMBL726694 | 0.86 | SMN1; SMN2 (0.56) | LMNAPOLBSMN1; SMN2GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023239729-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-14 | — | — | WO | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | disclosed |
| EP-2560955-B1 | NOVEL BENZAMIDE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-9221790-B2 | Benzamide derivatives | DONG-A PHARM. CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | DONG-A PHARM. CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560955-A2 | NOVEL BENZAMIDE DERIVATIVES | Dong-A Pharm.Co., Ltd. (KR) | 2013-02-27 | — | — | EP | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-0859607-A4 | GUANIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0859607-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997011693-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | HTR4, GPR4, HTR5A | LMNA 4050/4885POLB 4794/4885SMN1; SMN2 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.